KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Short-term Investments: 2013-2018

Historic Short-term Investments for Travere Therapeutics (TVTX) over the last 3 years, with Jun 2018 value amounting to $166.4 million.

  • Travere Therapeutics' Short-term Investments fell 19.51% to $166.4 million in Q2 2018 from the same period last year, while for Jun 2018 it was $166.4 million, marking a year-over-year decrease of 19.51%. This contributed to the annual value of $201.2 million for FY2017, which is 6.35% down from last year.
  • Latest data reveals that Travere Therapeutics reported Short-term Investments of $166.4 million as of Q2 2018, which was down 18.01% from $202.9 million recorded in Q1 2018.
  • Travere Therapeutics' Short-term Investments' 5-year high stood at $250.4 million during Q3 2016, with a 5-year trough of $5.9 million in Q2 2015.
  • Moreover, its 3-year median value for Short-term Investments was $203.9 million (2017), whereas its average is $205.3 million.
  • In the last 5 years, Travere Therapeutics' Short-term Investments skyrocketed by 7,085.29% in 2014 and then declined by 19.51% in 2018.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Short-term Investments stood at $9.6 million in 2014, then skyrocketed by 1,907.11% to $191.8 million in 2015, then increased by 12.03% to $214.9 million in 2016, then decreased by 6.35% to $201.2 million in 2017, then declined by 19.51% to $166.4 million in 2018.
  • Its last three reported values are $166.4 million in Q2 2018, $202.9 million for Q1 2018, and $201.2 million during Q4 2017.